{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:30:57Z","timestamp":1780342257901,"version":"3.54.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2020.576436","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T06:59:20Z","timestamp":1605077960000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Fulminant Course of Neuromyelitis Optica in a Patient With Anti-MDA5 Antibody-Positive Dermatomyositis: A Case Report"],"prefix":"10.3389","volume":"7","author":[{"given":"You-Ri","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Seung","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Hwa","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Wook","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Yong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopalakrishnan","family":"Chandrasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myeong-Kyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","article-title":"The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody","volume":"49","author":"Nakashima","year":"2010","journal-title":"Rheumatology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3109\/s10165-012-0663-4","article-title":"Anti-CADM-140\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease","volume":"23","author":"Sato","year":"2013","journal-title":"Mod Rheumatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"26552","DOI":"10.18632\/oncotarget.15716","article-title":"Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jneuroim.2014.07.016","article-title":"Dermatomyositis as a presentation of neuromyelitis optica spectrum disorder","volume":"278","author":"Delman","year":"2015","journal-title":"J Neuroimmunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/bjd.16917","article-title":"Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis","volume":"180","author":"Zhang","year":"2019","journal-title":"Br J Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3109\/14397595.2014.900843","article-title":"Serum interferon-alpha is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis","volume":"25","author":"Horai","year":"2015","journal-title":"Mod Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"713519","DOI":"10.1155\/2013\/713519","article-title":"Interferon alpha association with neuromyelitis optica","volume":"2013","author":"Asgari","year":"2013","journal-title":"Clin Dev Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s00415-013-7202-x","article-title":"Fulminant myelitis with NMO IgG antibody following treatment with interferon alpha","volume":"261","author":"Usmani","year":"2014","journal-title":"J Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1474-4422(19)30445-4","article-title":"Neuromyelitis optica in patients with increased interferon alpha concentrations","volume":"19","author":"Williams","year":"2020","journal-title":"Lancet Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/s10875-018-0563-2","article-title":"JAK 1\/2 blockade in MDA5 gain-of-function","volume":"38","author":"McLellan","year":"2018","journal-title":"J Clin Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation","volume":"340","author":"Gabay","year":"1999","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/intimm\/dxx031","article-title":"Hyperferritinemia and inflammation","volume":"29","author":"Kernan","year":"2017","journal-title":"Int Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","article-title":"Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","article-title":"Effectiveness of rituximab in neuromyelitis optica: a meta-analysis","volume":"19","author":"Gao","year":"2019","journal-title":"BMC Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4137\/CCRPM.S23313","article-title":"Recent treatment of interstitial lung disease with idiopathic inflammatory myopathies","volume":"9","author":"Kawasumi","year":"2015","journal-title":"Clin Med Insights Circ Respir Pulm Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","article-title":"Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis","volume":"37","author":"So","year":"2018","journal-title":"Clin Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2169\/internalmedicine.56.7956","article-title":"Dermatomyositis with rapidly progressive interstitial lung disease treated with rituximab: a report of 3 cases in Japan","volume":"56","author":"Tokunaga","year":"2017","journal-title":"Intern Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1212\/NXI.0000000000000061","article-title":"Disease exacerbation after rituximab induction in neuromyelitis optica","volume":"2","author":"Perumal","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jocn.2010.12.011","article-title":"Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels","volume":"18","author":"Nakashima","year":"2011","journal-title":"J Clin Neurosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/1346-8138.15117","article-title":"Elevated serum B-cell activating factor levels in patients with dermatomyositis: association with interstitial lung disease","volume":"46","author":"Matsushita","year":"2019","journal-title":"J Dermatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.576436\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T06:59:22Z","timestamp":1605077962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.576436\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":23,"alternative-id":["10.3389\/fmed.2020.576436"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.576436","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,11]]},"article-number":"576436"}}